GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

Search

Ocugen Inc

Open

1.52 -1.3

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.49

Max

1.54

Belangrijke statistieken

By Trading Economics

Inkomsten

611K

-15M

Verkoop

-108K

1.4M

Winstmarge

-1,073.489

Werknemers

95

EBITDA

724K

-13M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+459.21% upside

Dividenden

By Dow Jones

Volgende Winsten

5 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

188M

506M

Vorige openingsprijs

2.82

Vorige sluitingsprijs

1.52

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Ocugen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 okt 2025, 23:50 UTC

Populaire aandelen

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 okt 2025, 23:25 UTC

Winsten

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 okt 2025, 23:18 UTC

Winsten

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 okt 2025, 22:20 UTC

Winsten

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 okt 2025, 22:13 UTC

Winsten

Wal-Mart de Mexico Net Profit Falls in 3Q

28 okt 2025, 21:38 UTC

Winsten

Correction to Visa Sales Jump Article

28 okt 2025, 21:17 UTC

Winsten

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 okt 2025, 21:07 UTC

Winsten

Visa Sales Jump as Consumers Keep Spending -- Update

28 okt 2025, 21:02 UTC

Winsten

Mondelez Tempers Outlook as Costs Rise

28 okt 2025, 23:51 UTC

Marktinformatie

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 okt 2025, 23:42 UTC

Marktinformatie

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 okt 2025, 23:02 UTC

Winsten

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 okt 2025, 23:01 UTC

Winsten

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 okt 2025, 22:46 UTC

Winsten

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 okt 2025, 22:45 UTC

Winsten

SK Hynix 3Q Net KRW12.6T >000660.SE

28 okt 2025, 22:44 UTC

Winsten

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 okt 2025, 22:43 UTC

Winsten

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 okt 2025, 22:42 UTC

Winsten

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 okt 2025, 22:40 UTC

Winsten

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 okt 2025, 22:40 UTC

Winsten

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 okt 2025, 22:20 UTC

Winsten

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 okt 2025, 22:02 UTC

Winsten

Review & Preview: Earnings Extravaganza -- Barrons.com

28 okt 2025, 21:42 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

28 okt 2025, 21:42 UTC

Marktinformatie
Winsten

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 okt 2025, 21:20 UTC

Winsten

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 okt 2025, 21:19 UTC

Winsten

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 okt 2025, 21:18 UTC

Winsten

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer Vergelijking

Prijswijziging

Ocugen Inc Prognose

Koersdoel

By TipRanks

459.21% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8.5 USD  459.21%

Hoogste 15 USD

Laagste 4 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ocugen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.6818 / 0.74Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat